The trials showed an effect on Alzheimer’s biomarkers, though Novo did not specify which ones.
GLP-1s fail to slow progression of Alzheimer’s: Novo Nordisk
The trials showed an effect on Alzheimer’s biomarkers, though Novo did not specify which ones.